Patients undergoing primary total hip replacement were included in this randomized controlled trial to evaluate the comparative efficacy of oral and intravenous tranexamic acid (TXA) in reducing blood loss and limiting the need for blood transfusions. The number of patients included in this trial was not clearly reported in the conference abstract, but a power calculation was conducted that indicated a need for 50 patients in each group. The results of this trial indicate that there were no significant differences in postoperative hemoglobin drop, transfusion rate, or complication rate observed between groups.